Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders

References

• Marzano A, Angelucci E, Andreone P, et al. Prophylaxis and treatment of Hepatitis B in immunocompromised patients. Dig Liver Dis. 2007;39:397–408.
   PubMedGoogle Scholar
• Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263–283.
   PubMed Web of Science ®Google Scholar
• Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–662.
   PubMed Web of Science ®Google Scholar
• European Association for Study of Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–185.
   PubMed Web of Science ®Google Scholar
• Di Bisceglie AM, Lok AS, Martin P, et al. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology. 2015;61:703–711.
   PubMed Web of Science ®Google Scholar
• Reddy KR, Beavers KL, Hammond SP, et al.; American Gastroenterological Association Institute. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:215–217.
   PubMed Web of Science ®Google Scholar
• Hwang JP, Somerfield MR, Alston-Johnson DE, et al. Hepatitis B virus screening for patients with cancer before therapy: american society of clinical oncology provisional clinical opinion update. J Clin Oncol. 2015;33:2212–2220.
   PubMed Web of Science ®Google Scholar
• Alter MJ. Epidemiology and prevention of hepatitis B. Semin Liver Dis. 2003;23:39–46.
   PubMed Web of Science ®Google Scholar
• Hwang JP, Lok AS-F. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol. 2014;11:209–219.
   PubMed Web of Science ®Google Scholar
• Raimondo G, Pollicino T, Cacciola I, et al. Occult hepatitis B virus infection. J Hepatol. 2007;46:160–170.
   PubMed Web of Science ®Google Scholar
• Kim HY, Kim W. Chemotherapy-related reactivation of Hepatitis B infection: updates in 2013. World J Gastroenterol. 2014;20:14581–14588.
   PubMed Web of Science ®Google Scholar
• Gurcan HM, Keskin DB, Stern JNH, et al. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol. 2009;9:10–25.
   PubMed Web of Science ®Google Scholar
• Viganò M, Mangia G, Lampertico P. Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy. Expert Opin Biol Ther. 2014;14:1019–1031.
   PubMed Web of Science ®Google Scholar
• Ng HJ, Lim LC. Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report. Ann Hematol. 2001;80:549–552.
   PubMed Web of Science ®Google Scholar
• Skrabs C, Muller C, Agis H, et al. Treatment of HBV-carrying lymphoma patients with rituximab and CHOP: a diagnostic and therapeutic challenge. Leukemia. 2002;16:1884–1886.
   PubMed Web of Science ®Google Scholar
• Domingo-Domenech E, Gonzalez-Borco E, Estany C, et al. Combined treatment with anti CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas. Haematologica. 2002;87:1229–1230.
   PubMed Web of Science ®Google Scholar
• Jaeger G, Neumeister P, Brezinschek R, et al. Rituximab (anti-CD20 monoclonal antibody) as consolidation of first line CHOP chemotherapy in patients with follicular lymphoma: a phase II study. Eur J Haematol. 2002;69:21–26.
   PubMed Web of Science ®Google Scholar
• Hernandez JA, Diloy R, Salat D, et al. Fulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab. Haematologica. 2003;88:ECR22.
   PubMedGoogle Scholar
• Tsutsumi Y, Kawamura T, Saitoh S, et al. Hepatitis B virus reactivation in a case of Non-Hodgkin’s lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma. 2004;45:627–629.
   PubMed Web of Science ®Google Scholar
• Zell JA, Yoon EJ, Ignatius Ou SH, et al. Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab. Anticancer Drugs. 2005;16:83–85.
   PubMed Web of Science ®Google Scholar
• Dillon R, Hirschfield GM, Allison ME, et al. Fatal reactivation of hepatitis B after chemotherapy for lymphoma. BMJ. 2008;337:a423.
   PubMed Web of Science ®Google Scholar
• Wasmuth JC, Fischer HP, Sauerbruch T, et al. Fatal acute liver failure due to reactivation of hepatitis B following treatment with fludarabine cyclophosphamide rituximab for low grade non Hodgkin’s lymphoma. Eur J Med Res. 2008;13:483–486.
   PubMed Web of Science ®Google Scholar
• Marino D, Boso C, Crivellari G, et al. Fatal HBV-related liver failure during lamivudine therapy in a patient with non-Hodgkin’s lymphoma. Tumori. 2008;94:748–749.
   PubMed Web of Science ®Google Scholar
• Kusumoto S, Tanaka Y, Mizokami M, et al. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol. 2009;90:13–23.
   PubMed Web of Science ®Google Scholar
• Aomatsu T, Komatsu H, Yoden A, et al. Fulminant hepatitis B and acute hepatitis B due to intrafamilial transmission of HBV after chemotherapy for non-Hodgkin’s lymphoma in an HBV carrier. Eur J Pediatr. 2010;169:167–171.
   PubMed Web of Science ®Google Scholar
• Rago A, Lichtner M, Mecarocci S, et al. Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen. Antivir Ther. 2010;15:929–932.
   PubMed Web of Science ®Google Scholar
• Stange MA, Tutarel O, Pischke S, et al. Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: role of rituximab. Z Gastroenterol. 2010;48:258–263.
   PubMed Web of Science ®Google Scholar
• Leung C, Tsoi E, Burns G, et al. An argument for the universal prophylaxis of hepatitis B infection in patients receiving rituximab: a 7-year institutional experience of hepatitis screening. Oncologist. 2011;16:579–584.
   PubMed Web of Science ®Google Scholar
• Sperl J, Frankova S, Kieslichova E, et al. Urgent liver transplantation for chemotherapy-induced HBV reactivation: a suitable option in patients recently treated for malignant lymphoma. Transplant Proc. 2013;45:2834–2837.
   PubMed Web of Science ®Google Scholar
• Oh MJ, Lee HJ. A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experience. Clin Mol Hepatol. 2013;19:51–59.
   PubMedGoogle Scholar
• Yang SH, Kuo SH. Reactivation of hepatitis B virus during rituximab treatment of a patient with follicular lymphoma. Ann Hematol. 2008;87:325–327.
   PubMed Web of Science ®Google Scholar
• Perceau G, Diris N, Estines O, et al. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol. 2006;155:1053–1056.
   PubMed Web of Science ®Google Scholar
• Hanbali A, Khaled Y. Incidence of hepatitis B reactivation following Rituximab therapy. Am J Hematol. 2009;84:195.
   PubMed Web of Science ®Google Scholar
• Tsutsumi Y, Shigematsu A, Hashino S, et al. Analysis of reactivation of hepatitis B virus in the treatment of B cell non-Hodgkin’s lymphoma in Hokkaido. Ann Hematol. 2009;88:375–377.
   PubMed Web of Science ®Google Scholar
• Pei S-N, Chen C-H, Lee C-M, et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg negative patients. Ann Hematol. 2010;89:255–262.
   PubMed Web of Science ®Google Scholar
• Koo YX, Tan DSW, Tan IB, et al. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy. Cancer. 2010;116:115–121.
   PubMed Web of Science ®Google Scholar
• Mendez-Navarro J, Corey KE, Zheng H, et al. Hepatitis B screening, prophylaxis and reactivation in the era of rituximab-based chemotherapy. Liver Int. 2011;31:330–339.
   PubMed Web of Science ®Google Scholar
• Chen XQ, Peng JW, Lin GN, et al. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy. Med Oncol. 2012;29:1237–1241.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Hsu C, Song YQ, et al. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group. Eur J Cancer. 2013;49:3486–3496.
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan TC, Leung NWY, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27:605–611.
   PubMed Web of Science ®Google Scholar
• Mozessohn L, Chan KK, Feld JJ, et al. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis. J Viral Hepat. 2015;22:842–849.
   PubMed Web of Science ®Google Scholar
• Li H, Zhang HM, Chen LF, et al. Prophylactic lamivudine to improve the outcome of HBsAg-positive lymphoma patients during chemotherapy: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2015;39:80–92.
   PubMed Web of Science ®Google Scholar
• Li HR, Huang JJ, Guo HQ, et al. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J Viral Hepat. 2011;18:877–883.
   PubMed Web of Science ®Google Scholar
• Huang H, Li X, Zhu J, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA. 2014;312:2521–2530.
   PubMed Web of Science ®Google Scholar
• Kusumoto S, Tanaka Y, Suzuki R, et al. Monitoring of hepatitis B virus (HBV) DNA and risk of HBV reactivation in B-cell lymphoma: a prospective observational study. Clin Infect Dis. 2015;61:719–729.
   PubMed Web of Science ®Google Scholar
• Tamori A, Hino M, Kawamura E, et al. Prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy. J Gastroenterol Hepatol. 2014;29:1715–1721.
   PubMed Web of Science ®Google Scholar
• Hsu C, Tsou HH, Lin SJ, et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology. 2014;59:2092–2100.
   PubMed Web of Science ®Google Scholar
• Huang YH, Hsiao LT, Hong YC, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol. 2013;31:2765–2772.
   PubMed Web of Science ®Google Scholar
• Viganò M, Grossi G, Borsotti E, et al. Lamivudine prophylaxis prevents hepatitis B reactivation in HBsAg-negative/anti-HBc-positive patients undergoing Rituximab-based chemotherapy for non-Hodgkin’s B cell lymphoma. J Hepatol. 2015;62:S566.
   Google Scholar
• Pyrpasopoulou A, Douma S, Vassiliadis T, et al. Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int. 2011;31:403–404.
   PubMed Web of Science ®Google Scholar
• Ghrénassia E, Mékinian A, Rouaghe S, et al. Reactivation of resolved hepatitis B during rituximab therapy for rheumatoid arthritis. Joint Bone Spine. 2012;79:100–101.
   PubMed Web of Science ®Google Scholar
• Gigi E, Georgiou T, Mougiou D, et al. Hepatitis B reactivation in a patient with rheumatoid arthritis with antibodies to hepatitis B surface antigen treated with rituximab. Hippokratia. 2013;17:91–93.
   PubMed Web of Science ®Google Scholar
• Salman-Monte TC, Lisbona MP, García-Retortillo M, et al. Reactivation of hepatitis virus B infection in a patient with rheumatoid arthritis after treatment with rituximab. Reumatol Clin. 2014;10:196–197.
   PubMedGoogle Scholar
• Mitroulis I, Hatzara C, Kandili A, et al. Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis. 2013;72:308–310.
   PubMed Web of Science ®Google Scholar
• Barone M, Notarnicola A, Lopalco G, et al. Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. Hepatology. 2015;62:40–46.
   PubMed Web of Science ®Google Scholar
• Viganò M, Varisco V, Lampertico P, et al. Low risk of hepatitis B virus reactivation in HBsAg negative/anti-HBc positive carriers undergoing rituximab for rheumatoid arthritis. Dig Liver Dis. 2014;46:e23.
   Google Scholar
• Rituxan® (rituximab) package insert. [ cited 2015 Jun]. http://www.gene.com/download/pdf/rituxan_prescribing.pdf.
   Google Scholar
• Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med. 2004;350:2167–2179.
   PubMed Web of Science ®Google Scholar
• Seetharam A, Perrillo R, Gish R. Immunosuppression in patients with Chronic Hepatitis B. Curr Hepatol Rep. 2014;13:235–244.
   PubMedGoogle Scholar
• Carroll MB, Bond MI. Use of tumor necrosis factor-α inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum. 2008;38:208–217.
   PubMed Web of Science ®Google Scholar
• Viganò M, Degasperi E, Aghemo A, et al. Anti-TNF drugs in patients with Hepatitis B or C virus infection: safety and clinical management. Expert Opin Biol Ther. 2012;12:193–207.
   PubMed Web of Science ®Google Scholar
• Perez-Alvarez R, Diaz-Lagares C, Garcia-Hernandez F, et al. Hepatitis B Virus (HBV) reactivation in patients receiving Tumor Necrosis Factor (TNF) targeted therapy: analysis of 257 cases. Medicine (Baltimore). 2011;90:359–371.
   PubMed Web of Science ®Google Scholar
• Lan JL, Chen YM, Hsieh TY, et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis. 2011;70:1719–1725.
   PubMed Web of Science ®Google Scholar
• Cantini F, Boccia S, Goletti D, et al. HBV reactivation in patients treated with antitumor necrosis factor-alpha (TNF-α) agents for rheumatic and dermatologic conditions: a systematic review and meta-analysis. Int J Rheumatol. 2014;2014:926836.
   PubMedGoogle Scholar
• Vassilopoulos D, Apostolopoulou A, Hadziyannis E, et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis. 2010;69:1352–1355.
   PubMed Web of Science ®Google Scholar
• Ye H, Zhang XW, Mu R, et al. Anti-TNF therapy in patients with HBV infection- analysis of 87 patients with inflammatory arthritis. Clin Rheumatol. 2014;33:119–123.
   PubMed Web of Science ®Google Scholar
• Chung S-J, Kim JK, Park MC, et al. Reactivation of Hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor alpha therapy. J Rheumatol. 2009;36:2416–2420.
   PubMed Web of Science ®Google Scholar
• Remicade package insert. [ cited 2015 Jun]. www.remicade.com/shared/product/remicade/prescribing-information.pdf.
   Google Scholar
• Kuroda T, Wada Y, Kobayashi D, et al. Effect of etanercept and entecavir in a patient with rheumatoid arthritis who is a hepatitis B carrier: a review of the literature. Rheumatol Int. 2012;32:1059–1063.
   PubMed Web of Science ®Google Scholar
• Navarro R, Villarasa E, Herranz P, et al. Safety and effectiveness of ustekinumab and anti tumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicenter study in a clinical setting. British J Dermatol. 2013;168:609–616.
   PubMed Web of Science ®Google Scholar
• Chiu HY, Chen CH, Wu MS, et al. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol. 2013;169:1295–1303.
   PubMed Web of Science ®Google Scholar
• Steglich RB, Meneghello LP, Carvalho AVED, et al. The use of ustekinumab in a patient with severe psoriasis and positive HBV serology. An Bras Dermatol. 2014;89:652–654.
   PubMed Web of Science ®Google Scholar
• Morisco F, Guarino M, La Bella S, et al. Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis. BMC Gastroenterol. 2014;14:214.
   PubMed Web of Science ®Google Scholar
• Iannitto E, Minardi V, Calvaruso G, et al. Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol. 2005;74:254–258.
   PubMed Web of Science ®Google Scholar
• Cortelezzi A, Viganò M, Zilioli VR, et al. Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H. J Clin Virol. 2006;35:467–469.
   PubMed Web of Science ®Google Scholar
• Sharma A, Thompson JA, Repaka A, et al. Ipilimumab administration in patients with advanced melanoma and hepatitis B and C. J Clin Oncol. 2013;31:e370–e372.
   PubMed Web of Science ®Google Scholar
• Ravi S, Spencer K, Ruisi M, et al. Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series. J Immunother Cancer. 2014;2:33.
   PubMedGoogle Scholar
• Chmiel KD, Suan D, Liddle C, et al. Resolution of severe ipilimumab induced hepatitis after antithymocyte globulin therapy. J Clin Oncol. 2011;29:e237–e240.
   PubMed Web of Science ®Google Scholar
• Mitka M. FDA: increased HBV reactivation risk with ofatumumab or rituximab. JAMA. 2013;310:1664.
   PubMed Web of Science ®Google Scholar
• Nagashima T, Minota S. Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B. Rheumatology. 2008;47:1838–1840.
   PubMed Web of Science ®Google Scholar
• Tsuboi H, Tsujii A, Nampei A, et al. A patient with rheumatoid arthritis treated with tocilizumab together with lamivudine prophylaxis after remission of infliximab reactivated hepatitis B. Mod Rheumatol. 2011;21:701–705.
   PubMed Web of Science ®Google Scholar
• Kishida D, Okuda Y, Onishi M, et al. Successful tocilizumab treatment in a patient with adult-onset Still’s disease complicated by chronic active hepatitis B and amyloid A amyloidosis. Mod Rheumatol. 2011;21:215–218.
   PubMed Web of Science ®Google Scholar
• Nakamura J, Nagashima T, Nagatani K, et al. Reactivation of hepatitis B virus in rheumatoid arthritispatients treated with biological disease-modifying antirheumaticdrugs. Int J Rheum Dis. 2014. Epub ahead of print.
   Google Scholar
• Kim PS, Ho GY, Prete PE, et al. Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B. Arthritis Care Res (Hoboken). 2012;64:1265–1268.
   PubMed Web of Science ®Google Scholar
• Germanidis G, Hytiroglou P, Zakalka M, et al. Reactivation of occult hepatitis B virus infection, following treatment of refractory rheumatoid arthritis with abatacept. J Hepatol. 2012;56:1420–1421.
   PubMed Web of Science ®Google Scholar
• Fanouriakis A, Vassilopoulos D, Repa A, et al. Hepatitis B reactivation following treatment with abatacept in a patient with past hepatitis B virus infection. Rheumatology. 2014;53:195–196.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Shiga Y, Takahashi A, et al. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma. 2006;47:155–157.
   PubMed Web of Science ®Google Scholar
• Kim SG, Chun JM, Jin R, et al. Living donor liver transplantation for acute hepatic failure caused by reactivation of hepatitis B virus infection after chemotherapy for hematologic malignancy: case reports. Transplant Proc. 2010;42:843–845.
   PubMed Web of Science ®Google Scholar
• Kang BW, Lee SJ, Moon JH, et al. Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review. Int J Hematol. 2009;90:383–387.
   PubMed Web of Science ®Google Scholar
• Wang YD, Cui GH, Li M, et al. Hepatitis B virus reactivation in a chronic myeloid leukemia patient treated with imatinib mesylate. Chin Med J. 2012;125:2636–2637.
   PubMed Web of Science ®Google Scholar
• Lai GM, Yan SL, Chang CS, et al. Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor. World J Gastroenterol. 2013;19:1318–1321.
   PubMed Web of Science ®Google Scholar
• Walker EJ, Simko JP, Ko AH. Hepatitis B viral reactivation secondary to imatinib treatment in a patient with gastrointestinal stromal tumor. Anticancer Res. 2014;34:3629–3634.
   PubMed Web of Science ®Google Scholar
• Seggewis R, Lore’ K, Greiner E, et al. Imatininb inhibits T-cell-receptor mediated T-cell proliferation and activation in a dose-dependent manner. Blood. 2005;105:2473–2479.
   PubMed Web of Science ®Google Scholar
• Cwynarski K, Laylor R, Macchiarulo E, et al. Imatinib inhibits the activation and proliferation of normal T Lymphocytes in vitro. Leukemia. 2004;18:1332–1339.
   PubMed Web of Science ®Google Scholar
• Ando T, Kojima K, Isoda H, et al. Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia. Int J Hematol. 2015;102:379–382.
   PubMed Web of Science ®Google Scholar
• Blanco B, Perez-Simon JA, Sanchez-Abarca L, et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood. 2006;107:3575–3583.
   PubMed Web of Science ®Google Scholar
• Hussain S, Jhaj R, Ahsan S, et al. Bortezomib induced Hepatitis B reactivation. Case Rep Med. 2014;2014:964082.
   PubMedGoogle Scholar
• Mya DHT, Han ST, Linn YC, et al. Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection. Ann Oncol. 2012;23:421–426.
   PubMed Web of Science ®Google Scholar
• Goldberg R, Smith E, Bell S, et al. Bortezomib monotherapy in patients with Multiple Myeloma is associated with reactivation of Hepatitis B. Intern Med J. 2013;43:835–836.
   PubMed Web of Science ®Google Scholar
• Li J, Huang B, Li Y, et al. Hepatitis B virus reactivation in patients with multiple myeloma receiving bortezomib-containing regimens followed by autologous stem cell transplant. Leuk Lymphoma. 2015;56:1710–1717.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Sakuma I, Hashimoto S, et al. Hepatitis B reactivation in a multiple myeloma patient with resolved hepatitis B infection during bortezomib therapy: case report. J Clin Exp Hematop. 2012;52:67–69.
   PubMedGoogle Scholar
• Mizuno S, Yamagishi Y, Ebinuma H, et al. Progressive liver failure induced by everolimus for renal cell carcinoma in a 58-year-old male hepatitis B virus carrier. Clin J Gastroenterol. 2013;6:188–192.
   PubMedGoogle Scholar
• Sezgin Göksu S, Bilal S, Coşkun HŞ. Hepatitis B reactivation related to everolimus. World J Hepatol. 2013;5:43–45.
   PubMedGoogle Scholar